|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TUBA1C |
Gene summary for TUBA1C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TUBA1C | Gene ID | 84790 |
| Gene name | tubulin alpha 1c | |
| Gene Alias | TUBA6 | |
| Cytomap | 12q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | B7Z1K5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84790 | TUBA1C | GSM4909285 | Human | Breast | IDC | 1.51e-12 | 4.90e-01 | 0.21 |
| 84790 | TUBA1C | GSM4909286 | Human | Breast | IDC | 3.58e-05 | -2.74e-01 | 0.1081 |
| 84790 | TUBA1C | GSM4909294 | Human | Breast | IDC | 3.39e-02 | -1.94e-01 | 0.2022 |
| 84790 | TUBA1C | GSM4909296 | Human | Breast | IDC | 4.08e-06 | -1.25e-01 | 0.1524 |
| 84790 | TUBA1C | GSM4909297 | Human | Breast | IDC | 6.58e-13 | -2.49e-01 | 0.1517 |
| 84790 | TUBA1C | GSM4909298 | Human | Breast | IDC | 1.78e-09 | -3.65e-01 | 0.1551 |
| 84790 | TUBA1C | GSM4909301 | Human | Breast | IDC | 4.45e-09 | -3.91e-01 | 0.1577 |
| 84790 | TUBA1C | GSM4909302 | Human | Breast | IDC | 5.04e-03 | -2.86e-01 | 0.1545 |
| 84790 | TUBA1C | GSM4909311 | Human | Breast | IDC | 4.11e-27 | -3.72e-01 | 0.1534 |
| 84790 | TUBA1C | GSM4909312 | Human | Breast | IDC | 3.56e-09 | -1.41e-01 | 0.1552 |
| 84790 | TUBA1C | GSM4909313 | Human | Breast | IDC | 6.22e-07 | -3.65e-01 | 0.0391 |
| 84790 | TUBA1C | GSM4909315 | Human | Breast | IDC | 3.66e-02 | 2.52e-01 | 0.21 |
| 84790 | TUBA1C | GSM4909319 | Human | Breast | IDC | 2.55e-34 | -2.90e-01 | 0.1563 |
| 84790 | TUBA1C | GSM4909320 | Human | Breast | IDC | 1.73e-02 | -1.70e-01 | 0.1575 |
| 84790 | TUBA1C | GSM4909321 | Human | Breast | IDC | 5.10e-12 | -2.76e-01 | 0.1559 |
| 84790 | TUBA1C | brca1 | Human | Breast | Precancer | 4.63e-15 | 5.17e-01 | -0.0338 |
| 84790 | TUBA1C | brca2 | Human | Breast | Precancer | 2.87e-17 | 4.76e-01 | -0.024 |
| 84790 | TUBA1C | brca3 | Human | Breast | Precancer | 1.43e-21 | 5.34e-01 | -0.0263 |
| 84790 | TUBA1C | brca10 | Human | Breast | Precancer | 7.92e-13 | 5.25e-01 | -0.0029 |
| 84790 | TUBA1C | M2 | Human | Breast | IDC | 4.55e-07 | 4.67e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00307057 | Cervix | CC | cytoskeleton-dependent intracellular transport | 40/2311 | 195/18723 | 7.92e-04 | 6.99e-03 | 40 |
| GO:003070513 | Cervix | N_HPV | cytoskeleton-dependent intracellular transport | 13/534 | 195/18723 | 4.03e-03 | 3.16e-02 | 13 |
| GO:00307058 | Endometrium | AEH | cytoskeleton-dependent intracellular transport | 38/2100 | 195/18723 | 4.72e-04 | 4.91e-03 | 38 |
| GO:003070514 | Endometrium | EEC | cytoskeleton-dependent intracellular transport | 39/2168 | 195/18723 | 4.40e-04 | 4.58e-03 | 39 |
| GO:003070517 | Esophagus | HGIN | cytoskeleton-dependent intracellular transport | 45/2587 | 195/18723 | 3.07e-04 | 5.15e-03 | 45 |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:003070511 | Liver | Cirrhotic | cytoskeleton-dependent intracellular transport | 68/4634 | 195/18723 | 9.54e-04 | 6.77e-03 | 68 |
| GO:003070521 | Liver | HCC | cytoskeleton-dependent intracellular transport | 111/7958 | 195/18723 | 3.25e-05 | 3.28e-04 | 111 |
| GO:003070510 | Oral cavity | OSCC | cytoskeleton-dependent intracellular transport | 113/7305 | 195/18723 | 6.03e-08 | 1.09e-06 | 113 |
| GO:003070516 | Oral cavity | LP | cytoskeleton-dependent intracellular transport | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
| GO:003070523 | Oral cavity | EOLP | cytoskeleton-dependent intracellular transport | 42/2218 | 195/18723 | 8.11e-05 | 9.69e-04 | 42 |
| GO:003070531 | Oral cavity | NEOLP | cytoskeleton-dependent intracellular transport | 46/2005 | 195/18723 | 1.81e-07 | 6.18e-06 | 46 |
| GO:00307059 | Prostate | BPH | cytoskeleton-dependent intracellular transport | 68/3107 | 195/18723 | 3.78e-10 | 1.98e-08 | 68 |
| GO:003070515 | Prostate | Tumor | cytoskeleton-dependent intracellular transport | 67/3246 | 195/18723 | 6.56e-09 | 2.53e-07 | 67 |
| GO:003070519 | Skin | AK | cytoskeleton-dependent intracellular transport | 40/1910 | 195/18723 | 1.29e-05 | 2.58e-04 | 40 |
| GO:0030705110 | Skin | SCCIS | cytoskeleton-dependent intracellular transport | 20/919 | 195/18723 | 1.50e-03 | 1.69e-02 | 20 |
| GO:003070524 | Skin | cSCC | cytoskeleton-dependent intracellular transport | 77/4864 | 195/18723 | 2.32e-05 | 2.67e-04 | 77 |
| GO:003070520 | Thyroid | HT | cytoskeleton-dependent intracellular transport | 23/1272 | 195/18723 | 6.91e-03 | 4.21e-02 | 23 |
| GO:0030705111 | Thyroid | PTC | cytoskeleton-dependent intracellular transport | 104/5968 | 195/18723 | 3.87e-10 | 1.24e-08 | 104 |
| GO:003070525 | Thyroid | goiters | cytoskeleton-dependent intracellular transport | 14/497 | 195/18723 | 7.37e-04 | 1.68e-02 | 14 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513229 | Prostate | Tumor | Salmonella infection | 98/1791 | 249/8465 | 2.55e-11 | 5.28e-10 | 3.27e-10 | 98 |
| hsa0453029 | Prostate | Tumor | Tight junction | 69/1791 | 169/8465 | 3.92e-09 | 6.18e-08 | 3.83e-08 | 69 |
| hsa0513029 | Prostate | Tumor | Pathogenic Escherichia coli infection | 77/1791 | 197/8465 | 5.20e-09 | 7.77e-08 | 4.82e-08 | 77 |
| hsa0421025 | Prostate | Tumor | Apoptosis | 48/1791 | 136/8465 | 9.03e-05 | 6.10e-04 | 3.78e-04 | 48 |
| hsa0414527 | Prostate | Tumor | Phagosome | 52/1791 | 152/8465 | 1.19e-04 | 7.42e-04 | 4.60e-04 | 52 |
| hsa0501237 | Prostate | Tumor | Parkinson disease | 144/1791 | 266/8465 | 3.33e-33 | 1.10e-30 | 6.83e-31 | 144 |
| hsa0502036 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
| hsa0501636 | Prostate | Tumor | Huntington disease | 150/1791 | 306/8465 | 2.72e-28 | 2.25e-26 | 1.40e-26 | 150 |
| hsa0501036 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
| hsa0501436 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
| hsa0502236 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
| hsa0513237 | Prostate | Tumor | Salmonella infection | 98/1791 | 249/8465 | 2.55e-11 | 5.28e-10 | 3.27e-10 | 98 |
| hsa0453037 | Prostate | Tumor | Tight junction | 69/1791 | 169/8465 | 3.92e-09 | 6.18e-08 | 3.83e-08 | 69 |
| hsa0513037 | Prostate | Tumor | Pathogenic Escherichia coli infection | 77/1791 | 197/8465 | 5.20e-09 | 7.77e-08 | 4.82e-08 | 77 |
| hsa0421035 | Prostate | Tumor | Apoptosis | 48/1791 | 136/8465 | 9.03e-05 | 6.10e-04 | 3.78e-04 | 48 |
| hsa0414535 | Prostate | Tumor | Phagosome | 52/1791 | 152/8465 | 1.19e-04 | 7.42e-04 | 4.60e-04 | 52 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TUBA1C | SNV | Missense_Mutation | novel | c.672N>T | p.Met224Ile | p.M224I | protein_coding | deleterious_low_confidence(0.02) | benign(0.127) | TCGA-A2-A0CV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TUBA1C | SNV | Missense_Mutation | c.1477N>A | p.Glu493Lys | p.E493K | protein_coding | deleterious_low_confidence(0.01) | benign(0.282) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| TUBA1C | SNV | Missense_Mutation | c.302N>T | p.Gln101Leu | p.Q101L | protein_coding | deleterious_low_confidence(0.02) | benign(0.012) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| TUBA1C | SNV | Missense_Mutation | rs571434095 | c.1226N>A | p.Arg409His | p.R409H | protein_coding | deleterious_low_confidence(0.05) | benign(0.125) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| TUBA1C | SNV | Missense_Mutation | novel | c.1060N>C | p.Glu354Gln | p.E354Q | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TUBA1C | SNV | Missense_Mutation | rs371063872 | c.851N>A | p.Arg284His | p.R284H | protein_coding | tolerated_low_confidence(0.12) | benign(0.013) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |
| TUBA1C | SNV | Missense_Mutation | c.430N>A | p.Val144Ile | p.V144I | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.734) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| TUBA1C | SNV | Missense_Mutation | novel | c.995A>C | p.Tyr332Ser | p.Y332S | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.685) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TUBA1C | SNV | Missense_Mutation | novel | c.995A>C | p.Tyr332Ser | p.Y332S | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.685) | TCGA-BH-A1FR-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| TUBA1C | SNV | Missense_Mutation | c.392A>G | p.His131Arg | p.H131R | protein_coding | deleterious_low_confidence(0.02) | benign(0.147) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 84790 | TUBA1C | DRUGGABLE GENOME | inhibitor | CHEMBL378544 | VINBLASTINE SULFATE | |
| 84790 | TUBA1C | DRUGGABLE GENOME | inhibitor | CHEMBL49642 | INDIBULIN | |
| 84790 | TUBA1C | DRUGGABLE GENOME | VINORELBINE BASE | VINORELBINE | 25768699 | |
| 84790 | TUBA1C | DRUGGABLE GENOME | 4-(PHENYLCARBAMOYL)BENZYLNITRATE | CHEMBL1795737 | 21664138 | |
| 84790 | TUBA1C | DRUGGABLE GENOME | VINBLASTINE | VINBLASTINE | 23708010,23916255 | |
| 84790 | TUBA1C | DRUGGABLE GENOME | inhibitor | CHEMBL1683544 | ERIBULIN MESYLATE | |
| 84790 | TUBA1C | DRUGGABLE GENOME | CHEMBL2103826 | DAVUNETIDE | ||
| 84790 | TUBA1C | DRUGGABLE GENOME | CYCLOSTREPTIN | CYCLOSTREPTIN | 17206139 | |
| 84790 | TUBA1C | DRUGGABLE GENOME | inhibitor | CHEMBL1201748 | CABAZITAXEL | |
| 84790 | TUBA1C | DRUGGABLE GENOME | VORINOSTAT | VORINOSTAT | 20491440 |
| Page: 1 2 3 4 5 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |